Phase 1B study of the safety and tolerability of the mineralocorticoid fludrocortisone acetate in patients with geographical atrophy

Documenti analoghi

• Effect of AZD9977 and spironolactone on serum potassium in heart failure with preserved or mildly reduced ejection fraction, and renal impairment: A randomized trial
  di: Iain B. Squire, et al.
  Pubblicazione: (2022-10-01)
• Preclinical pharmacology of AZD9977: A novel mineralocorticoid receptor modulator separating organ protection from effects on electrolyte excretion.
  di: Krister Bamberg, et al.
  Pubblicazione: (2018-01-01)
• Navafenterol (AZD8871) in healthy volunteers: safety, tolerability and pharmacokinetics of multiple ascending doses of this novel inhaled, long-acting, dual-pharmacology bronchodilator, in two phase I, randomised, single-blind, placebo-controlled studies
  di: Victor Balaguer, et al.
  Pubblicazione: (2020-09-01)
• Navafenterol (AZD8871) in patients with mild asthma: a randomised placebo-controlled phase I study evaluating the safety, tolerability, pharmacokinetics, and pharmacodynamics of single ascending doses of this novel inhaled long-acting dual-pharmacology bronchodilator
  di: Eulalia Jimenez, et al.
  Pubblicazione: (2020-09-01)
• The novel mineralocorticoid receptor modulator balcinrenone protects against diet-induced cardiac microvascular dysfunction and plasma potassium elevation in mouse models.
  di: Matthew J Wolf, et al.
  Pubblicazione: (2026-01-01)